Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sesame Care vs Boston Medical Group

Two GLP-1 desks, one scoreboard. We put Sesame Care and Boston Medical Group head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 4 · Grade B+

Sesame Care

Visit Sesame Care Full brief →
vs
No. 152 · Grade C

Boston Medical Group

Visit Boston Medical Group Full brief →

The verdict

Sesame Care takes this head-to-head.

Sesame Care scores 87 to 68 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

That doesn't make Boston Medical Group a bad call — it's best for readers who want budget-conscious shoppers. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
48
Supply Reliability
92
74
Transparency
94
88
Access Breadth
84
46
Clinical Oversight
80
82
Track Record
92
77
Sesame CareBrief Score 87 · 68Boston Medical Group

Price, coverage & the tracker

Sesame CareBoston Medical Group
Brief Score87/100 (B+)68/100 (C)
SemaglutideFrom $149/mo (brand Wegovy pill)From $66/mo (starting dose, compounded)
TirzepatideBrand Zepbound (price varies)Not disclosed
CoverageNationwide marketplace7 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

Boston Medical Group: New to the tracker on 1 August 2026. The published line reads From $66/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.